Boston Trust Walden Corp Reduces Holdings in Chemed Corporation $CHE

Boston Trust Walden Corp decreased its holdings in Chemed Corporation (NYSE:CHE) by 5.2% in the 3rd quarter, Holdings Channel reports. The firm owned 234,466 shares of the company’s stock after selling 12,968 shares during the period. Chemed accounts for about 0.8% of Boston Trust Walden Corp’s investment portfolio, making the stock its 26th biggest holding. Boston Trust Walden Corp’s holdings in Chemed were worth $104,980,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in CHE. Creekmur Asset Management LLC acquired a new stake in shares of Chemed in the second quarter valued at approximately $28,000. WPG Advisers LLC purchased a new position in shares of Chemed during the 1st quarter worth $32,000. Parkside Financial Bank & Trust boosted its stake in Chemed by 86.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 95 shares of the company’s stock worth $46,000 after buying an additional 44 shares during the last quarter. HM Payson & Co. raised its stake in Chemed by 35.5% during the third quarter. HM Payson & Co. now owns 103 shares of the company’s stock worth $46,000 after purchasing an additional 27 shares during the period. Finally, Geneos Wealth Management Inc. raised its stake in shares of Chemed by 330.4% in the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after acquiring an additional 76 shares during the period. 95.85% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on CHE shares. Weiss Ratings restated a “hold (c-)” rating on shares of Chemed in a report on Wednesday, October 8th. Bank of America lowered their target price on Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a report on Wednesday, September 10th. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 30th. Royal Bank Of Canada reduced their price target on shares of Chemed from $589.00 to $572.00 and set an “outperform” rating for the company in a research note on Monday, November 10th. Finally, Jefferies Financial Group upgraded Chemed from a “hold” rating to a “buy” rating and upped their target price for the stock from $490.00 to $550.00 in a research report on Tuesday, September 2nd. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $574.25.

Chemed Stock Performance

Shares of NYSE:CHE opened at $432.58 on Monday. Chemed Corporation has a one year low of $408.42 and a one year high of $623.60. The company has a market capitalization of $6.13 billion, a PE ratio of 22.88, a price-to-earnings-growth ratio of 2.41 and a beta of 0.46. The stock has a fifty day moving average of $435.54 and a 200-day moving average of $454.06.

Chemed (NYSE:CHE) last released its quarterly earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). The company had revenue of $624.90 million during the quarter, compared to analyst estimates of $626.04 million. Chemed had a net margin of 11.02% and a return on equity of 25.89%. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter last year, the business earned $5.64 EPS. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, research analysts forecast that Chemed Corporation will post 21.43 EPS for the current fiscal year.

Chemed Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Monday, November 17th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Monday, November 17th. Chemed’s dividend payout ratio is 12.69%.

Insider Buying and Selling

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $437.55, for a total transaction of $875,100.00. Following the transaction, the chief executive officer directly owned 94,197 shares in the company, valued at approximately $41,215,897.35. The trade was a 2.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.29% of the company’s stock.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.